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Abstract 
Here we report a case of glioblastoma (GB) 
with leptomeningeal dissemination (LMD) in a 21 
year old female presenting with generalized tonic-
clonic seizures. After a brain MRI confirmed a non-
enhancing left frontal lobe mass, histopathological 
examination and molecular analysis showed a 
glioblastoma with features of gliosarcoma that was 
an IDH wild type, MGMT unmethylated, TERT 
amplified tumor. She received standard care with 
combined chemoradiation with temozolomide and 
targeted radiation. MRI showing disease 
progression prompted the addition of bevacizumab 
after which the patient quickly deteriorated and died 
eight months after initial presentation. Incidence of 
LMD is an uncommon occurrence and associated 
with a significant decrease in overall survival when 
diagnosed at initial presentation. More research is 
needed to determine what role histopathologic 
variants and molecular profile plays in prognosis 
and treatment.    
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Case Report 
A 21-year-old lady presented in September 
2016 with a generalized tonic-clonic seizure. For a 
few weeks prior to presentation, the patient had also 
noticed increasingly worsening headaches. She 
reported a medical history of attention deficit 
hyperactivity disorder (ADHD) and anxiety. Her 
family history included hypertension, diabetes, and 
asthma.  A neurological exam at presentation was 
normal. Routine bloodwork was unremarkable. 
MRI brain done at the time of presentation showed 
a non-enhancing left frontal lobe mass as shown in 
Figure 1A.  
The patient was offered a resection of the mass 
but failed to attend her follow-up appointment. Four 
months after initial presentation, a repeat MRI 
showed change in the radiographic characteristics 
with significant increase in size, development of 
necrosis, heterogeneous enhancement and evidence 
of leptomeningeal spread (Figure 1B, black arrows). 
Leptomeningeal spread along the spine was not 
demonstrated with a spinal MRI.   The patient had a 
subtotal resection (Figure 2A) with histology 
showing this to be glioblastoma (GB) with 
gliosarcoma features and evidence of subarachnoid 
involvement (Figure 3).  Molecular studies showed 
an Isocitrate dehydrogenase (IDH) wild type, O6-
methylguanine DNA methyltransferase (MGMT) 
unmethylated, Telomerase reverse transcriptase 
(TERT) amplified tumor. These genetic alterations 
are associated with poorer prognosis and a more 
aggressive disease course.  
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Figure 1: A. Axial T2 sequence showing increased T2 signal abnormality in the left frontal lobe (black arrow) 
B. Axial T1 post contrast sequence showing a large necrotic, heterogeneously enhancing mass in the left frontal
lobe. Black arrows point to areas concerning for leptomeningeal spread of tumor with enhancement seen within
the sulci. C. Axial FLAIR sequence shows large T2 hyper-intense mass, significantly increased in size 
compared to original presentation 4 months earlier (Figure 1 A) 
Figure 2: A. Axial T1 post contrast sequence showing post operative scan. Note persistent evidence of 
leptomeningeal disease (black arrow). B. Axial T1 post contrast sequence prior to initiation of concurrent 
radiation and chemotherapy shows significant recurrence of disease over a 4 week period from prior scan. C. 
Axial T1 post contrast sequence post completion of concurrent radiation and chemotherapy shows further 
progression of disease. Note significant dural involvement of disease (black arrowheads) 
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Figure 3: Histological characteristics of glioblastoma. This low power view demonstrates one of the most 
recognizable characteristics of GBM showing small foci of necrosis surrounded by centrifugally oriented glial 
cells creating a pseudopalisading appearance (40x objective) B) A higher magnification shows necrosis (*) and 
pseudopalisades (arrows, 100x). The rapid proliferation of neoplastic glial cells makes the brain parenchyma 
appear much more cellular. Additionally, the tumor eventually outgrows it’s blood supply and cells begin to 
die, creating foci of necrosis. C) The cell morphology of glioblastoma shows small, pleomorphic cells with 
clumpy, irregular chromatin and occasional prominent nucleoli. Many mitoses (*) can be seen and correlates 
with the increased aggressiveness of glioblastoma (400x). D) Subarachnoid spread of the tumor is 
demonstrated. Normal brain parenchyma appears less cellular in the upper half of the frame. Tumor is 
adherent of the molecular layer of cerebral cortex (arrows, 40x). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Repeat MRI brain done 3 weeks later prior to 
initiation of radiation (RT) and chemotherapy 
showed significant recurrence of disease.(Figure 
2B) The patient was treated  by standard of care 
treatment for GB consisting of 6 weeks of intensity 
modulated radiation therapy (IMRT) with a total 
dose of 60Gy in 30 fractions and temozolomide, an 
alkylating chemotherapeutic agent. Post completion 
of RT and temozolomide, repeat MRI showed 
further progression. (Figure 2C) She received 1 
dose of bevacizumab, a VEGF inhibitor approved 
for the treatment of recurrent GB but passed away 
one day after infusion and eight months after initial 
presentation. CT scan of the brain done a day prior 
to her passing away showed increased mass effect 
and rightward midline shift.  (Figure 4) There was 
also marked effacement of the left lateral ventricle 
and third ventricle. After the initial seizure at 
presentation, she was started on prophylactic anti-
epileptics (leviteracetam 750mg bid) and steroids. 
Throughout the disease course she experienced 
neurological symptoms including headaches, right 
sided weakness (hemiparesis), and anger outburst 
that were likely related to frontal lobe involvement 
of the tumor. Despite treatment, her disease 
continued to progress.    
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Figure 4: CT head without contrast shows progression of disease with increased size of left inferior frontal and 
temporal lobe heterogeneous masses. Increased mass effect with effacement of adjacent sulci and increased 
effacement of the left lateral ventricle. There is rightward midline shift. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GB is the most common primary brain tumor in 
adults. Despite advances in surgical techniques, 
radiation treatments and chemotherapy, it continues 
to have a dismal prognosis with a median overall 
survival of around 14-16 months.1-2,4 Surprisingly, 
given the location of glioblastoma in the central 
nervous system and relatively high exposure of the 
ventricular system during tumor resection, the 
incidence of leptomeningeal dissemination (LMD) 
is thought to be uncommon though data on the 
subject is scarce. In a recent retrospective study of 
595 patients with a diagnosis of glioblastoma 
enrolled in clinical trials, only 4% of these patients 
developed LMD.3 Patients who were diagnosed 
with LMD at time of diagnosis of glioblastoma, as 
was the case in the patient described above, had a 
worse prognosis compared to those who were 
diagnosed afterwards (estimated overall survival of 
4.7 months compared to 16.0 months). This 
emphasizes the need to develop better therapies that 
specifically target tumor cells within the 
cerebrospinal fluid. 
With regard to the histopathology and genetics, 
one study looking at 20 cases demonstrated that the 
85% of cases with LMD were IDH wild type, in 
keeping with our case.5 Of these cases, 50% were of 
the small cell variant of GB and one was a 
gliosarcoma variant, all of which were IDH1 wild 
type.5 This genetic profile carries a well described 
poorer prognosis than IDH mutants in addition to 
MGMT unmethylated status and TERT mutations.6  
There is a paucity of research describing in detail 
the molecular character of GB with LMD and what 
role these attributes play in the clinical course. In 
our case, overall survival was approximately 8 
months from the time of diagnosis of GB with 
LMD. This is a better outcome than the 4.7 months 
overall survival reported by Mandel et al.3 More 
research in this area in needed to see if the 
histopathological variant or molecular profile affect 
prognosis and therefore have treatment 
implications.   
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